Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study.
Tim M GoversDaphne HesselsVirginie Vlaeminck-GuillemBernd J Schmitz-DrägerChristian G StiefClaudio Martinez-BallesterosMatteo FerroAngel Borque-FernandoJose Rubio-BrionesJ P Michiel SedelaarWim van CriekingeJack A SchalkenPublished in: Prostate cancer and prostatic diseases (2018)
The results of the model showed that with SelectMDx, QALYs could be gained while saving healthcare costs in the initial diagnosis of prostate cancer. The significant presence of overtreatment in the current standard of care in all four countries was the main factor that resulted in the beneficial outcomes with SelectMDx.